These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24707144)

  • 1. Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease.
    Thomas D; Gazouli M; Karantanos T; Rigoglou S; Karamanolis G; Bramis K; Zografos G; Theodoropoulos GE
    World J Gastroenterol; 2014 Apr; 20(13):3609-14. PubMed ID: 24707144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of miR-146 rs2910164, miR-196a rs11614913, miR-221 rs113054794 and miR-224 rs188519172 polymorphisms with anti-TNF treatment response in a Greek population with Crohn's disease.
    Papaconstantinou I; Kapizioni C; Legaki E; Xourgia E; Karamanolis G; Gklavas A; Gazouli M
    World J Gastrointest Pharmacol Ther; 2017 Nov; 8(4):193-200. PubMed ID: 29152405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.
    Louis E; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Malaise M; Belaiche J
    Scand J Gastroenterol; 2002 Jul; 37(7):818-24. PubMed ID: 12190096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease.
    Netz U; Carter JV; Eichenberger MR; Dryden GW; Pan J; Rai SN; Galandiuk S
    World J Gastroenterol; 2017 Jul; 23(27):4958-4967. PubMed ID: 28785150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis.
    Lacruz-Guzmán D; Torres-Moreno D; Pedrero F; Romero-Cara P; García-Tercero I; Trujillo-Santos J; Conesa-Zamora P
    Eur J Clin Pharmacol; 2013 Mar; 69(3):431-8. PubMed ID: 22960943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease.
    Willot S; Vermeire S; Ohresser M; Rutgeerts P; Paintaud G; Belaiche J; De Vos M; Van Gossum A; Franchimont D; Colombel JF; Watier H; Louis E
    Pharmacogenet Genomics; 2006 Jan; 16(1):37-42. PubMed ID: 16344720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
    Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
    Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L
    BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab in clinical routine: experience with Crohn's disease and biomarkers of inflammation over 5 years.
    Lönnkvist MH; Befrits R; Lundberg JO; Lundahl J; Fagerberg UL; Hjortswang H; van Hage M; Hellström PM
    Eur J Gastroenterol Hepatol; 2009 Oct; 21(10):1168-76. PubMed ID: 19757522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation.
    Lu C; Waugh A; Bailey RJ; Cherry R; Dieleman LA; Gramlich L; Matic K; Millan M; Kroeker KI; Sadowski D; Teshima CW; Todoruk D; Wong C; Wong K; Fedorak RN
    World J Gastroenterol; 2012 Sep; 18(36):5058-64. PubMed ID: 23049214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.
    Billiet T; Cleynen I; Ballet V; Claes K; Princen F; Singh S; Ferrante M; Van Assche G; Gils A; Vermeire S
    Scand J Gastroenterol; 2017 Oct; 52(10):1086-1092. PubMed ID: 28622097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tumor necrosis factor-related apoptosis-inducing ligand gene polymorphism and its plasma phenotype in relation to Crohn's disease].
    Zhu HQ; Hu P; Xu F; Shao XX; Cao SG; Wu H; Jiang Y
    Zhonghua Yi Xue Za Zhi; 2023 Feb; 103(8):585-593. PubMed ID: 36822870
    [No Abstract]   [Full Text] [Related]  

  • 14. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
    J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn's disease.
    Matsukura H; Ikeda S; Yoshimura N; Takazoe M; Muramatsu M
    Aliment Pharmacol Ther; 2008 May; 27(9):765-70. PubMed ID: 18248655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of response to infliximab in paediatric perianal Crohn's disease.
    Dupont-Lucas C; Dabadie A; Alberti C; Ruemmele FM;
    Aliment Pharmacol Ther; 2014 Oct; 40(8):917-29. PubMed ID: 25146368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-TNF therapy in treatment of luminal Crohn's disease].
    Marko B; Prka L
    Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab.
    Mascheretti S; Hampe J; Kühbacher T; Herfarth H; Krawczak M; Fölsch UR; Schreiber S
    Pharmacogenomics J; 2002; 2(2):127-36. PubMed ID: 12049175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elective switching from infliximab to adalimumab in stable Crohn's disease.
    Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
    Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between tumor necrosis factor-alpha and Fc-gamma receptor polymorphisms with infliximab in Crohn's disease.
    Tomita K; Chiba T; Sugai T; Habano W
    Hepatogastroenterology; 2010; 57(99-100):535-9. PubMed ID: 20698223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.